• Earlier in June 2026, a Delaware jury found that Amgen willfully infringed Harbour BioMed’s Grosveld patent, awarding Harbour US$20,203,704 in damages, while Amgen also released new Phase 3 VESALIUS-CV data showing Repatha reduced major cardiovascular events in high-risk diabetes patients and secured European approval for its lung cancer drug Imdylltra.
• The combination of a patent loss in antibody discovery technology and clinically meaningful Repatha outcomes, alongside Imdylltra’s new EU indication, highlights how intellectual property risks and late-stage trial successes can pull Amgen’s longer-term prospects in different directions at the same time.
• We’ll now examine how Repatha’s cardiovascular outcomes data and Imdylltra’s European approval could reshape Amgen’s investment narrative around chronic disease growth.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Amgen Investment Narrative Recap

To own Amgen today, you generally need to believe that its broad biologics portfolio and late-stage pipeline can offset pricing pressure, biosimilar competition, and higher R&D spend. Against that backdrop, the Harbour BioMed patent verdict and evolving Repatha and Imdylltra data do not obviously change the near term focus on execution in chronic cardiometabolic disease and oncology, or the most immediate overhang from tax and pricing scrutiny.

The most directly relevant update is the new Phase 3 VESALIUS-CV subgroup data for Repatha in high risk diabetes, which reinforces its role in primary cardiovascular prevention. For shareholders watching Amgen’s transition away from aging blockbusters, this kind of outcomes evidence sits at the heart of the near term growth story in chronic disease, even as legal, tax, and regulatory issues create parallel uncertainties around the equity case.

Yet behind Amgen’s solid chronic disease story, investors should be aware of how pricing reforms and an unresolved IRS dispute could...

Amgen's narrative projects $40.1 billion revenue and $9.9 billion earnings by 2029. This requires 2.5% yearly revenue growth and a $2.1 billion earnings increase from $7.8 billion today.

Uncover how Amgen's forecasts yield a $352.23 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a much tougher picture, assuming revenues around US$37.1 billion and earnings near US$7.9 billion by 2029, so if you worry about overreliance on aging drugs and rising tax and pricing headwinds, it is worth comparing that more cautious view with how Repatha’s new data and the latest legal developments might eventually shift both sets of expectations.

Explore 4 other fair value estimates on Amgen - why the stock might be worth just $352.23!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.